George Sledge responds to Berry’s letter: Neoadjuvant doesn’t predict adjuvant in breast cancer and Berry’s rejoinder

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As always, I both enjoyed and learned something interesting from Dr. Don Berry, one of the great biostatisticians of our era. I find, reading his analysis of ALTTO and NeoALTTO, much that I agree with. I am certainly no statistician, and must bow to his statistical analysis of ALTTO and NeoALTTO. And yet at the same time I think it misses the point. So I will beg to differ.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
George W. Sledge Jr.
Chief of oncology, Stanford University
Donald A. Berry
Professor of biostatistics, MD Anderson Cancer Center

YOU MAY BE INTERESTED IN

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening. 
George W. Sledge Jr.
Chief of oncology, Stanford University
Donald A. Berry
Professor of biostatistics, MD Anderson Cancer Center

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login